Osteoprotegerin (OPG), human recombinant protein
Osteoprotegerin, OPG
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | O14788 |
---|---|
Calculated MW | 20.0 kDa |
Gene ID | 8600 |
---|---|
Gene Symbol | OPG |
Other Names | Osteoprotegerin, OPG, Tumor necrosis factor receptor superfamily member 11B, Osteoclastogenesis inhibitory factor, TNFRSF11B, OCIF |
Gene Source | Human |
Source | E. coli |
Assay&Purity | SDS-PAGE; ≥98% |
Assay2&Purity2 | HPLC; ≥98% |
Recombinant | Yes |
Results | 10 ng/ml |
Target/Specificity | Osteoprotegerin |
Application Notes | Reconstitute in 5 mM Tris, pH 7.5 to a concentration of 0.1-1.0 mg/ml. The solution can be diluted into other aqueous buffers and stored at 4°C for 1 week or –20°C for future use. |
Format | Lyophilized protein |
Storage | -20°C; Sterile filtered and then lyophilized |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Human OPG (Osteoprotegerin), also known as OCIF (Osteoclastogenesis inhibitory factor), is a member of the TNF receptor superfamily. Recombinant human OPG/OCIF specifically acts on bone tissues and increases bone mineral density and bone volume associated with a decrease of active osteoclast number. Recombinant human OPG is a 20 kDa protein, comprising of 174 amino acid residues.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.